Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: Correlation of complete response, time-to-event and overall survival end points

Annals of Oncology

Volumn 22, Issue 6, 2011, Pages 1392-1403

  Lee, L ^a   Wang, L ^a   Crump, M ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Clinical trials; Non Hodgkin's lymphoma; Surrogate end points

Indexed keywords

BLEOMYCIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; FOLINIC ACID; IDARUBICIN; INTERFERON; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PIRARUBICIN; PREDNIMUSTINE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; TENIPOSIDE; VINBLASTINE; VINCRISTINE; VINDESINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EVENT FREE SURVIVAL; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 79957864197     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq615     Document Type: Article

References (81)

1. Ng R, Pond GR, Tang PA et al. Correlation of changes between 2-year diseasefree survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006. Ann Oncol 2008; 19: 481-486.
2. Burzykowski T, Buyse M, Piccart-Gebhart MJ et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 2008; 26: 1987-1992.
3. Hotta K, Fujiwara Y, Matsuo K et al. Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer. J Thorac Oncol 2009; 4: 311-317.
4. Methy N, Bedenne L, Conroy T et al. Surrogate end points for overall survival and local control in neoadjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trial. Ann Oncol 2010; 21: 518-524.
5. Sargent DJ, Wieand HS, Haller DG et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005; 23: 8664-8670.
6. Buyse M, Burzykowski T, Carroll K et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007; 25: 5218-5224.
7. Tang PA, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 2007; 25: 4562-4568.
8. Gill S, Sargent D. End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival? Oncologist 2006; 11: 624-629.
9. Knox JJ. Progression-free survival as endpoint in metastatic RCC? Lancet 2008; 372: 427-429.
10. Appelbaum FR, Rosenblum D, Arceci RJ et al. End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood 2007; 109: 1810-1816.
11. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8: 431-440.
12. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996; 125: 605-613.
13. Buyse M, Molenberghs G, Burzykowski T et al. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 2000; 1: 49-67.
14. Begg CB, Leung DHY. On the use of surrogate end points in randomized trials. J R Stat Soc Ser A Stat Soc 2000; 163: 15-28.
15. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
16. Panageas KS, Ben-Porat L, Dickler MN et al. When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst 2007; 99: 428-432.
17. Saad ED, Katz A, Hoff PM, Buyse M. Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol 2010; 21: 7-12.
18. Mathoulin-Pelissier S, Gourgou-Bourgade S, Bonnetain F, Kramar A. Survival end point reporting in randomized cancer clinical trials: a review of major journals. J Clin Oncol 2008; 26: 3721-3726.
19. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
20. Herold M, Haas A, Srock S et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25: 1986-1992.
21. Marcus R, Imrie K, Solal-Celigny P et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26: 4579-4586.
22. Salles G, Mounier N, De Guibert S et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008; 112: 4824-4831.
23. Hagenbeek A, Eghbali H, Monfardini S et al. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV Lowgrade malignant non-Hodgkin's lymphoma. J Clin Oncol 2006; 24: 1590-1596.
24. Kimby E, Bjorkholm M, Gahrton G et al. Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol 1994; 5: 67-71.
25. Nickenig C, Dreyling M, Hoster E et al. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer 2006; 107: 1014-1022.
26. Tilly H, Lepage E, Coiffier B et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003; 102: 4284-4289.
27. Bernstein SH, Unger JM, Leblanc M et al. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516-the Southwest Oncology Group. J Clin Oncol 2009; 27: 114-119.
28. Larouche J-F, Berger F, Chassagne-Clement C et al. Lymphoma recurrence 5 years or later following diffuse large B-Cell lymphoma: clinical characteristics and outcome. J Clin Oncol 2010; 28: 2094-2100.
29. Guglielmi C, Gomez F, Philip T et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 1998; 16: 3264-3269.
30. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009; 101: 1642-1649.
31. van Oers MH, Van Glabbeke M, Giurgea L et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010; 28: 2853-2858.
32. Saville MW, Leonard JP, Hainsworth JD et al. Role of different frontline regimens in achieving complete response in follicular lymphoma: a meta-analysis of CR rate and its relation to hazard rate for disease progression. Blood (ASH Annual Meeting Abstracts) 2006; 108 (Abstr 2754).
33. Pfreundschuh M, Zwick C, Zeynalova S et al. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2008; 19: 545-552.
34. Pfreundschuh M, Trumper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with goodprognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.
35. Economopoulos T, Psyrri A, Dimopoulos MA et al. CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: results of the HE22A99 trial of the Hellenic Cooperative Oncology Group. Cancer J 2007; 13: 327-334.
36. Aviles A, Nambo MJ, Castaneda C et al. Rituximab and escalated chemotherapy in elderly patients with aggressive diffuse large-cell lymphoma: a controlled clinical trial. Cancer Biother Radiopharm 2007; 22: 194-199.
37. Verdonck LF, Notenboom A, De Jong DD et al. Intensified 12-week CHOP (ICHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 2007; 109: 2759-2766.
38. Merli F, Bertini M, Luminari S et al. Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2007; 48: 367-373.
39. Habermann TM, Weller EA, Morrison VA et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121-3127.
40. Burton C, Linch D, Hoskin P et al. A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma. Br J Cancer 2006; 94: 806-813.
41. Federico M, Luminari S, Gobbi PG et al. The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study. Eur J Haematol 2006; 76: 217-229.
42. Federico M, Clo V, Brugiatelli M et al. Efficacy of two different ProMACECytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL. Haematologica 1998; 83: 800-811.
43. Sonneveld P, van Putten W, Biesma D et al. Phase III trial of 2-weekly CHOP with rituximab for aggressive B-cell non-Hodgkin's lymphoma in elderly patients. Blood ASH Annual Meeting Abstracts 2006; 108 (Abstr 210).
44. Burton C, Smith P, Vaughan-Hudson G et al. Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma. Br J Haematol 2005; 130: 536-541.
45. Mori M, Kitamura K, Masuda M et al. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THPCOPE regimens in elderly patients with non-Hodgkin's lymphoma. Int J Hematol 2005; 81: 246-254.
46. Kinoshita T, Hotta T, Tobinai K et al. A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9002. Int J Hematol 2004; 80: 341-350.
47. Pfreundschuh M, Trumper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634-641.
48. Pfreundschuh M, Trumper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004; 104: 626-633.
49. Osby E, Hagberg H, Kvaloy S et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic lymphoma group randomized trial. Blood 2003; 101: 3840-3848.
50. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
51. Economopoulos T, Dimopoulos MA, Mellou S et al. Treatment of intermediateand high-grade non-Hodgkin's lymphoma using CEOP versus CNOP. Eur J Haematol 2002; 68: 135-143.
52. Mainwaring PN, Cunningham D, Gregory W et al. Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with highgrade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO. Blood 2001; 97: 2991-2997.
53. Giles FJ, Shan J, Advani SH et al. A prospective randomized study of Chop versus Chop plus Alpha-2B interferon in patients with Intermediate and High Grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 study. Leuk Lymphoma 2001; 40: 95-103.
54. Linch DC, Smith P, Hancock BW et al. A randomised British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma. Ann Oncol 2000; 11: S87-S90.
55. Jerkeman M, Anderson H, Cavallin-Stahl E et al. CHOP versus MACOP-B in aggressive lymphoma-a Nordic Lymphoma Group randomised trial. Ann Oncol 1999; 10: 1079-1086.
56. Bailey NP, Stuart NSA, Bessell EM et al. Five-year follow-up of a prospective randomised multi-centre trial of weekly chemotherapy (CAPOMEt) versus cyclical chemotherapy (CHOP-Mtx) in the treatment of aggressive non-Hodgkin's lymphoma. Central Lymphoma Group. Ann Oncol 1998; 9: 633-638.
57. Nair R, Ramakrishnan G, Nair NN et al. A randomized comparison of the efficacy and toxicity of epirubicin and doxorubicin in the treatment of patients with non-Hodgkin's lymphoma. Cancer 1998; 82: 2282-2288.
58. Cameron DA, White JM, Proctor SJ et al. CHOP-based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high-grade non-Hodgkin's lymphoma. Eur J Cancer 1997; 33: 1195-1201.
59. Brice P, Bastion Y, Lepage E et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15: 1110-1117.
60. Wolf M, Matthews JP, Stone J et al. Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin's lymphoma. Ann Oncol 1997; 8: S71-S75.
61. Sertoli MR, Santini G, Chisesi T et al. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the Non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 1994; 12: 1366-1374.
62. Silingardi V, Federico M, Cavanna L et al. ProMECE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma: long term results of a multicenter study of the Italian lymphoma study group (GISL). Leuk Lymphoma 1995; 17: 313-320.
63. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-1006.
64. Somers R, Carde P, Thomas J et al. EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma. Ann Oncol 1994; 5: 85-89.
65. Meyer RM, Quirt IC, Skillings JR et al. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 1770-1776.
66. Gordon LI, Harrington D, Andersen J et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992; 327: 1342-1349.
67. Mazza P, Zinzani PL, Martelli M et al. MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas. Leuk Lymphoma 1995; 16: 457-463.
68. Gottlieb AJ, Anderson JR, Ginsberg SJ et al. A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas. Cancer and Leukemia Group B study 7851. Cancer 1990; 66: 1888-1896.
69. Taylor PR, White JM, Prescott RJ et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leuk Lymphoma 2006; 47: 2321-2330.
70. Haynes A, McMillan A, Jack A et al. A prospective, randomised trial of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for advanced follicular lymphoma (real grades I-III, stages III/IV). ASH Annual Meeting Abstracts 2006; 108 (Abstr 534).
71. Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725-3732.
72. Peterson BA, Petroni GR, Frizzera G et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol 2003; 21: 5-15.
73. Smalley RV, Weller E, Hawkins MJ et al. Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin's lymphoma treated with interferon alfa (IFN-alpha2a) plus an anthracycline-based induction regimen. Leukemia 2001; 15: 1118-1122.
74. Unterhalt M, Herrmann R, Tiemann M et al. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. Leukemia 1996; 10: 836-843.
75. Solal-Celigny P, Lepage E, Brousse N et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med 1993; 329: 1608-1614.
76. Herold M, Schulze A, Niederwieser D et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol 2006; 132: 105-112.
77. Kalinka-Warzocha E, Wajs J, Lech-Maranda E et al. Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the polish lymphoma research group. Cancer 2008; 113: 367-375.
78. Foussard C, Colombat P, Gressin R et al. Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies. Ann Oncol 2005; 16: 466-472.
79. Tsimberidou AM, McLaughlin P, Younes A et al. Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. Blood 2002; 100: 4351-4357.
80. Coiffier B, Neidhardt-Berard EM, Tilly H et al. Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol 1999; 10: 1191-1197.
81. Arranz R, Garcia-Alfonso P, Sobrino P et al. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization. J Clin Oncol 1998; 16: 1538-1546.